---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-23-053086"
form_type: "8-K"
ticker: "GYRE"
cik: "0001124105"
company_name: "GYRE THERAPEUTICS, INC."
filed_at: "2023-11-14T23:59:59+00:00"
generated_at: "2026-06-08T03:11:49.202435+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# GNI Group, Gyre's controlling shareholder, reports 9M 2023 revenue ¥20.5B (+61%), net profit ¥2.2B (+106%)

## Summary
- 9M 2023 revenue of ¥20,547.9M, up 61% from ¥12,761.0M in prior year.
- Net profit attributable to parent ¥2,213.3M vs ¥1,076.1M, more than doubled.
- Operating cash flow ¥4,443.0M, turning from negative ¥162.9M in prior year.
- Total assets ¥48,468.0M, up 33% from ¥36,456.9M at prior year-end.
- Basic EPS ¥46.61 (9M) vs ¥22.67; diluted EPS ¥46.13 vs ¥22.46.

## SEC filing metadata
- accession: 0001140361-23-053086
- form_type: 8-K
- ticker: GYRE
- cik: 0001124105
- company_name: GYRE THERAPEUTICS, INC.
- filed_at: 2023-11-14T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1124105/000114036123053086/0001140361-23-053086-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1124105/000114036123053086/ny20009756x17_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-23-053086
- JSON: https://secwatch.observer/filing/0001140361-23-053086.json
- Plain text: https://secwatch.observer/filing/0001140361-23-053086.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.